Enhanced metabolism and negative regulation of ER stress support higher erythropoietin production in HEK293 cells.

ATF6B CP: Cell biology CP: Molecular biology Cell engineering GFP HEK293 erythropoietin protein production ribosome heterogeneity secretory pathways

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
14 06 2022
Historique:
received: 28 09 2020
revised: 05 01 2022
accepted: 18 05 2022
entrez: 15 6 2022
pubmed: 16 6 2022
medline: 18 6 2022
Statut: ppublish

Résumé

Recombinant protein production can cause severe stress on cellular metabolism, resulting in limited titer and product quality. To investigate cellular and metabolic characteristics associated with these limitations, we compare HEK293 clones producing either erythropoietin (EPO) (secretory) or GFP (non-secretory) protein at different rates. Transcriptomic and functional analyses indicate significantly higher metabolism and oxidative phosphorylation in EPO producers compared with parental and GFP cells. In addition, ribosomal genes exhibit specific expression patterns depending on the recombinant protein and the production rate. In a clone displaying a dramatically increased EPO secretion, we detect higher gene expression related to negative regulation of endoplasmic reticulum (ER) stress, including upregulation of ATF6B, which aids EPO production in a subset of clones by overexpression or small interfering RNA (siRNA) knockdown. Our results offer potential target pathways and genes for further development of the secretory power in mammalian cell factories.

Identifiants

pubmed: 35705050
pii: S2211-1247(22)00718-5
doi: 10.1016/j.celrep.2022.110936
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Erythropoietin 11096-26-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110936

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests P.-O.B. is cofounder and CEO of Biocrine AB. L.G. and D.H. are employees of AstraZeneca and may own AstraZeneca stock or stock options.

Auteurs

Rasool Saghaleyni (R)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden.

Magdalena Malm (M)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden.

Noah Moruzzi (N)

The Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institute, 17176 Stockholm, Sweden.

Jan Zrimec (J)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden.

Ronia Razavi (R)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden.

Num Wistbacka (N)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden.

Hannes Thorell (H)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden.

Anton Pintar (A)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden.

Andreas Hober (A)

Science for Life Laboratory, KTH - Royal Institute of Technology, 171 65 Solna, Sweden.

Fredrik Edfors (F)

Science for Life Laboratory, KTH - Royal Institute of Technology, 171 65 Solna, Sweden.

Veronique Chotteau (V)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Industrial Biotechnology, 106 91 Stockholm, Sweden.

Per-Olof Berggren (PO)

The Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institute, 17176 Stockholm, Sweden.

Luigi Grassi (L)

Cell Culture & Fermentation Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Aleksej Zelezniak (A)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden.

Thomas Svensson (T)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden; Department of Biology and Biological Engineering, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Chalmers University of Technology, Kemivägen 10, 41258 Gothenburg, Sweden.

Diane Hatton (D)

Cell Culture & Fermentation Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Jens Nielsen (J)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.

Jonathan L Robinson (JL)

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden; Department of Biology and Biological Engineering, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Chalmers University of Technology, Kemivägen 10, 41258 Gothenburg, Sweden. Electronic address: jonrob@chalmers.se.

Johan Rockberg (J)

KTH - Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology, and Health, Department of Protein Science, 106 91 Stockholm, Sweden. Electronic address: johan.rockberg@biotech.kth.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH